| |
 |
 |
1.Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, Su YL, Chen YH, Lu SN, Rau KM*. Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. Sci World J. 2014:160138 (non-SCI).
2.Su YL, Li SH, Chen YY , Chen HC, Tang Y, Huang CH, Chou FF, Wu SC, Rau KM*. Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Radiology and oncology. 2014;48:314-322. (SCI ; IF=1.746 ; Radiology, Nuclear medicine & Medical imaging 92/133;first author)
3.Su YL, Rau KM*. Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-positive Lung Adenocarcinoma. J Thorac Oncol. 2015; 10(4):e21-22 (SCI ; IF=13.357 ; Respiratory System 3/64)
4.Hsieh MC, Sung MT, Chiang PH, Huang CH, Tang Y, Su YL* : The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma. PLoS One. 2015 Jun 26;10(6):e0129268. (SCI; IF=2.740; Multidisciplinary sciences 27/71; Corresponding author)
5.Su YL, Chou CL, Rau KM, Charles Lee TC*. Asthma and Risk of Prostate Cancer: A Population-based Case-Cohort Study in Taiwan. Medicine, 2015; 94(36): e1371. (SCI ; IF=1.552 MEDICINE, GENERAL & INTERNAL 89/165)
6.Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH* : The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. Urol Oncol. 2015 Nov;33(11):495.e9-14. (SCI; IF=2.882; UROLOGY & NEPHROLOGY 28/85)
7.Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH*. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy. Int J Urol 2016; 23:385-389. (SCI; IF=2.445; UROLOGY & NEPHROLOGY 36/85)
8.Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chen YY, Chou WC*. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia Pac J Clin Oncol 2016; 12(4):396-402. (SCI; IF=2.012; Oncology 201/244)
9.Hsieh MC, Huang CH, Chiang PH, Chen YY, Tang Y, Su YL*. Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. J Cancer 2016; 27:1347-52. (SCI; IF=3.565; Oncology 105/244, Corresponding author )
10.Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH,
Rau KM*. A preliminary randomised controlled study of short-term Antrodia
cinnamomea treatment combined with chemotherapy for patients with advanced
cancer. BMC Complement Altern Med 2016; 16(1):322. (SCI; IF=2.833; Integrative
& Complementary medicine 6/28)
11.Lee WC, Liu WH, Su YL*. Left ventricular intracavitary and intramyocardial
metastases from renal cell carcinoma. J Echocardiogr. 2017; 15(3):143-144.
(non-SCI)
12.Su YL, Hsieh MC, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Hung CH,
Tang Y, Rau KM*. Novel Inflammation-Based Prognostic Score for Predicting
Survival in Patients with Metastatic Urothelial Carcinoma. PLOS One 10(6):
e0129268. (SCI; IF=2.740; Multidisciplinary sciences 27/71, first author)
13.Huang CC*, Fang FM, Chen HC, Hsu HC, Huang TL, Su YL, Chang YC.
Therapeutic outcome of nasopharyngeal carcinoma with cranial nerve palsy: a single
institution experience of 104 patients. OncoTargets Ther. 2017 Apr
10;10:2069-2075. (SCI; IF=3.337; Biotechnology & applied microbiology 56/156)
14.Petrylak DP, de Wit R, Chi KN…Su YL…et al. Ramucirumab plus docetaxel versus
placebo plus docetaxel in patients with locally advanced or metastatic urothelial
carcinoma after platinum-based therapy (RANGE): a randomised, double-blind,
phase 3 trial. Lancet. 2017; 390(10109):2266-2277. (SCI; IF=60.392; Medicine, General & internal 2/165)
15.Rau KM*, Su YL, Li SH, Hsieh, MC Wu CC, Chou FF, Chiu Tai Jan, Chen Yen
Hao, Liu Chien Tin. High expression of endoglin in primary breast cancer
may predict response to neoadjuvant chemotherapy. Mol Med Rep. 2017; 16(5):
7185-7190. (SCI; IF=2.100; Medicine, research & experimental 96/138)
16.Su YL*. Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab
in a Patient with Metastatic Clear-cell Renal Cell Carcinoma. Clin Genitourin
Cancer. 2018; 16(2):114-6. (SCI; IF=2.695; Urology & Nephrology 30/85)
17.Huang HS, Su YL, Li PH, Chiang PH, Huang CH, Chen CH, Hsieh MC*.
Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic
urothelial carcinoma receiving platinum based chemotherapy. Sci Rep. 2018;
8(1):7485. (SCI; IF=3.998; Multidisciplinary Sciences 17/71)
18.Huang PW, Chou WC, Shen WC, Hung CY, Huang KG, Su YL, Lu CH, Chang YS,
Liau CT*. Hand-foot skin reaction predicts treatment outcome of pazopanib in
patients with metastatic soft tissue sarcoma: A multicenter study in the Asian
population. Asia Pac J Clin Oncol 2018, 14:353-360. (SCI; IF=2.012; Oncology 201/244)
19.Hsieh MC, Rau KM, Chiang PH, Sung MT, Lan J, Luo HL, Huang CC, Huang CH,
Su YL*. Impact of Prognostic Nutritional Index on Overall Survival for Patients
with Metastatic Urothelial Carcinoma. J Cancer 2018, 14;9(14):2466-2471. (SCI; IF=3.565; Oncology 105/244, Corresponding author)
20.Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY*. A review of
Complementary therapies with medicinal plants for chemotherapy-induced
peripheral neuropathy. Complement Ther Med 2019; 42:226-323. (SCI; IF=2.063;
Integrative & Complementary medicine 14/28)
21.Lin JJ, Huang CC, Su YL, Luo HL, Lee NL, Wu YJ, Sung MT *. Proteomics
analysis of Tangeretin-induced apoptosis through mitochondrial dysfunction in
bladder cancer cells. Int J Mol Sci 2019; 20:E1017. (SCI; IF=4.556; Biochemistry &
Molecular Biology 74/297)
22.Huang CC, Su YL, Luo HL, Chen YT, Sio TT, Hsu HC, Lai CH*. Gender is a
significant prognostic factor for upper urinary tract urothelial carcinoma: A large
hospital-based cancer registry study in an endemic area. Front. Oncol. 9:157. (SCI;
IF=4.848; Oncology 69/244)
23.Huang CC, Chao PJ, Guo SS, Wang CJ, Luo HL, Su YL, Lee TF, Fang FM*.
Developing a multivariable normal tissue complication probability model to predict
late rectal bleeding following intensity-modulated radiation therapy. J Cancer 2019; 10(11):2588-2593. (SCI; IF=3.565; Oncology 105/244)
24.Luo HL, Chiang PH, Huang CC, Su YL, Sung MT, Tsai EM, Lin CS, Chiang PH*.
Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced
Upper Urinary Tract Urothelial Carcinoma. Int J Mol Sci 2019; 20(7):E1653. doi:
10.3390/ijms20071653. (SCI; IF=4.556; Biochemistry &
Molecular Biology 74/297)
25.Wu CC, Rau KM, Lee WC, Hsieh MC, Liu JC, Chen YY, Su YL*. Presence of
Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer
Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
(EGFR-TKI): A Nationwide, Population-Based Cohort Study. J Clin Med 2019,
8(7):1024. (SCI; IF=3.303; Medicine, General & internal 36/165, Corresponding
author)
26.Luo HL, Chen IH , Su YL, Huang CC, Chiang PH, Yu CC, Lee NL, Lin JJ, Sung
MT*. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through
the MAPK Pathway. Molecules 2019, 24(20): 3707. (SCI; IF=3.267; Chemistry,
multidisciplinary 70/177)
27.Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang
CC, Huang CH, Liu JM, Su YL*. Comparative study of the safety and efficacy of
first-line cisplatin and carboplatin chemotherapy in elderly patients with metastatic
urothelial carcinoma. Oncology 2020;98:146-153 (SCI; IF=2.642; Oncology 162/244, Corresponding author)
28.Liu YW, Liu CT, Su YL, Tsai MY. A Narrative Review of Complementary Nutritional Supplements for Chemotherapy-induced Peripheral Neuropathy. Altern Ther Health Med 2019 (SCI; IF=0.937; Integrative complementary medicine 25/28)
29.Petrylak DP, de Wit R, Chi KN…Su YL…et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019. (SCI; IF=33.752; Oncology 4/244)
30.Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med 2020; 9(1): E188. (SCI; IF=3.303; Medicine, General & internal 36/165)
31.Liu JM, Liu YP, Chuang HC, Wu CT, Su YL, Hsu RJ. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders. PLos One 2020; 15(2):e0229263. (SCI; IF=2.740; Multidisciplinary sciences 27/71)
32.Su YL*, Luo HL, Huang CC, Liu TT, Huang EY, Sung MT, Lin JJ, Chiang PH, Chen YT, Kang CH, Cheng YT. Galectin-1 overexpression activates the FAK/PI3K/AKT/mTOR pathway and is correlated with upper urinary urothelial carcinoma progression and survival. Cells 2020, 9(4):806 (SCI; IF=4.366; Cell biology, 70/195 First and corresponding author)
|
|
